Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261)

Overview

  • Product name
    Anti-Cisplatin modified DNA antibody [CP9/19]
  • Description
    Rat monoclonal [CP9/19] to Cisplatin modified DNA
  • Tested applications
    Suitable for: ELISA, Flow Cyt, Dot blotmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Cisplatin Modified Native DNA.

  • Positive control
    • RNA/DNA.
  • General notes


    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    Preservative: None
    Constituents: PBS
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Primary antibody notes
    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
  • Clonality
    Monoclonal
  • Clone number
    CP9/19
  • Myeloma
    Y3/Ag1.2.3
  • Isotype
    IgG2a
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab103261 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration. PubMed: 23370278

ab18450 - Rat IgG2a kappa monoclonal, is suitable for use as an isotype control with this antibody.

Dot blot Use at an assay dependent concentration. PubMed: 25356874

Images

  • ab103261 staining Cisplatin modified DNA in human ovarian cancer cell line A2780 by Flow Cytometry. Cells in culture were detached by accutase treatment, fixed with 70% ehtanol for 30 min at 4°C and permeabilized with 100ug/ml digitonin in PBS. The sample was incubated with the primary antibody (1/200 in PBS + 1% FBS) for 18 hours at 4°C. A FITC-conjugated rabbit anti-rat IgG H&L polyclonal (1/200) was used as the secondary antibody. Gating Strategy: FITC positive cells.

    The sh2 represents the gene knock down cell line which showed positive staining with anti-cisplatin adduct antibody upon cisplatin treatment, whereas the control cells (cis-R, resistant to cisplatin) did not show any staining with anti-cis adduct antibody upon cisplatin treatment.

    See Abreview

References

This product has been referenced in:
  • Hu J  et al. Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proc Natl Acad Sci U S A 113:11507-11512 (2016). Read more (PubMed: 27688757) »
  • Han C  et al. Differential DNA lesion formation and repair in heterochromatin and euchromatin. Carcinogenesis 37:129-38 (2016). Read more (PubMed: 26717995) »

See all 8 Publications for this product

Customer reviews and Q&As

Application
Flow Cytometry
Sample
Human Cell (human ovarian cancer cell line A2780)
Permeabilization
Yes - 100ug/ml digitonin in PBS
Gating Strategy
FITC positive cells
Specification
human ovarian cancer cell line A2780
Preparation
Cell harvesting/tissue preparation method: Cells in culture detached by accutase treatment
Sample buffer: PBS
Fixation
70% ehtanol for 30 min at 4 degrees
Username

Abcam user community

Verified customer

Submitted Apr 16 2015

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (ovarian cancer A2780 cell line)
Specification
ovarian cancer A2780 cell line
Permeabilization
Yes - 0.1% digitonin in PBS
Fixative
70% ethanol
Username

Abcam user community

Verified customer

Submitted Aug 25 2014

Regarding the question of whether ab103261 (Anti-Cisplatin modified DNA antibody [CP9/19]) recognizes adducts in chromatin or pure DNA, the antibody was raised against purified drug-modified DNA. For a number of reasons one would expect adducts on DNA ...

Read More

Thank you for your recent telephone enquiry and for your patience.

I apologize for the long delay in getting back to you. We have been waiting to receive further information from the originator of this antibody.

I am sorry to conf...

Read More

Thisantibody targets adducts present in polymeric DNA.


For any further information I would suggest the reference by Tilby et al. A pubmed link to this paper can be found under the 'Specific references' tab on the online product datashee...

Read More

Thank you very much for your interest in ab103261.

To our knowledge, ab103261 has not been tested in IHC and thereforewe do not have any protocol suggestions.

I can offer a discount off a future purchase if you buy ab103261 now, te...

Read More
Application
ELISA
Sample
Human Cell (melanoma)
Specification
melanoma
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 0.74µg/mL · Temperature: 20°C
Type
Direct
Username

Abcam user community

Verified customer

Submitted May 04 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up